Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Publication Name: Annals of Surgical Oncology

Author(s): Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD.

PURPOSE: The purpose of the NBRST study is to compare a multigene classifier to conventional immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) subtyping to predict chemosensitivity as defined by pathological complete response (pCR) or endocrine sensitivity as defined by partial response. … Continued

MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue.

Publication Name: The Journal of Molecular Diagnostics

Author(s): Sapino A, Roepman P, Linn SC, Snel MHJ, Delahaye LJMJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EMJJ, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox

MammaPrint, a prognostic 70-gene profile for early-stage breast cancer, has been available for fresh tissue. Improvements in RNA processing have enabled microarray diagnostics for formalin-fixed, paraffin- embedded (FFPE) tissue. Here, we describe method optimization, validation, and performance of MammaPrint using … Continued

Performance Characteristics of the MammaPrint Breast Cancer Diagnostic Gene Signature

Publication Name: Personalized Medicine

Author(s): Leonie JM Delahaye, Diederik Wehkamp, Arno N Floore, Rene Bernards, Laura J van‘t Veer1 & Annuska M Glas

The analytical performance of multigene signatures depends on many parameters, including precision, repeatability, reproducibility and intratumor heterogeneity. Indicators such as sensitivity, specificity, positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic … Continued

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Publication Name: International Journal of Cancer

Author(s): C.A. Drukker, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, R.M.H. Roumen, M. Knauer, L.J. van ’t Veer, G.S. Sonke, E.J.T. Rutgers, M.J. van de Vijver, S.C. Linn

The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene … Continued

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Publication Name: Annals of Surgical Oncology

Author(s): Bichlien Nguyen, Pino G. Cusumano, Kenneth Deck, Deborah Kerlin, Agustin A. Garcia, Julie L. Barone, Edgardo Rivera, Katharine Yao, Femke A. de Snoo, Jeroen van den Akker, Lisette Stork-Sloots, Daniele Generali

Purpose: To compare breast cancer subtyping with the three centrally assessed microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Methods: BluePrint, MammaPrint, and TargetPrint were all performed on … Continued

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

Publication Name: PLOS ONE

Author(s): Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland, Ron M. Kerkhoven, Iris Simon,Emiel J. Th. Rutgers, Lodewyk F. A. Wessels, Laura J. Van't Veer

Background and Methods: Formalin Fixed Paraffin Embedded (FFPE) samples represent a valuable resource for cancer research. However, the discovery and development of new cancer biomarkers often requires fresh frozen (FF) samples. Recently, the Whole Genome (WG) DASL (cDNA-mediated Annealing, Selection, … Continued

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

Publication Name: British Journal of Cancer

Author(s): M Knauer, F Cardoso, J Wesseling, PL Bedard, SC Linn, EJT Rutgers, and LJ van 't Veer

BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus … Continued

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer

Publication Name: International Journal of Molecular Medicine

Author(s): Heidrun Gevensleben, Uwe-Jochen Gohring, Reinhard Buttner. Lukas C. Heukamp, Georg Kunz, Thomas Dimpfl, Christian Jackisch, Olaf Ortmann, Ute-Susann Albert, Richard Bender, Femke De Snoo, Oscar Krijgsman, Annuska M. Glas

The 70-gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines. The microarray-based test TargetPrint further provides reliable, quantitative assessment of mRNA expression … Continued

Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

Publication Name: Japanese Journal of Clinical Oncology

Author(s): Makoto Ishitobi, Teodora Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska Glas, Ellen van Lienen, Hideo Inaji Laura van’t Veer and Kikuya Kato

Objective: van’t Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with … Continued

Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients

Publication Name: Archives of Gynecology and Obstetrics

Author(s): Georg Kunz

Purpose: Breast cancer as a heterogeneous disease demands reliable tools in order to identify those patients who most likely will benefit from receiving adjuvant treatment, such as chemotherapy. MATERIALS AND METHODS: The MammaPrint test was established on the basis of … Continued